Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | OGA | O60502 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12615500 | 0.82 | RXFP1 (0.46) | KMT2AMEN1NPC1RAB9AMAPT | |
| SCHEMBL22348008 | 0.81 | CYP1A2 (0.33) | KMT2AMEN1TSHRNPC1RAB9A | |
| SCHEMBL1581515 | 0.81 | CYP1A2 (0.37) | KMT2ATSHRNPC1RAB9AUSP2 | |
| SCHEMBL6068632 | 0.80 | HTR3A (0.51) | KMT2AKDM4EALDH1A1 | |
| SCHEMBL2263521 | 0.79 | CYP1A2 (0.40) | TSHRNPC1RAB9AUSP2GAA | |
| SCHEMBL496543 | 0.76 | HTT (0.44) | KMT2AMEN1TSHRNPC1RAB9A | |
| SCHEMBL9900463 | 0.76 | PLD1 (0.53) | KMT2AMEN1TSHRUSP2KDM4E | |
| SCHEMBL3517742 | 0.76 | PRKDC (0.40) | — | |
| SCHEMBL16834500 | 0.76 | KMT2A (0.47) | KMT2AMEN1TSHRRAB9AGAA | |
| SCHEMBL3518720 | 0.76 | PRKDC (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9321756-B2 | Azole compounds as PIM inhibitors | AMGEN INC. (US) | 2016-04-26 | — | — | US | claimed |
| US-9090593-B2 | Bicyclic compounds as Pim inhibitors | AMGEN INC. (US) | 2015-07-28 | — | — | US | claimed |
| EP-2796456-A1 | Bicyclic compounds as Pim inhibitors | Amgen Inc. (US) | 2014-10-29 | — | — | EP | claimed |
| US-20140187553-A1 | Azole Compounds as PIM Inhibitors | AMGEM INC. (US) | 2014-07-03 | — | — | US | claimed |
| US-20140031360-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2014-01-30 | — | — | US | claimed |
| EP-2688886-A1 | AZOLE COMPOUNDS AS PIM INHIBITORS | Amgen Inc. (US) | 2014-01-29 | — | — | EP | claimed |
| EP-2649065-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | Amgen Inc. (US) | 2013-10-16 | — | — | EP | claimed |
| WO-2012129338-A1 | AZOLE COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2012-09-27 | — | — | WO | claimed |
| WO-2012078777-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2012-06-14 | — | — | WO | claimed |
| US-9321756-B2 | Azole compounds as PIM inhibitors | AMGEN INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-9090593-B2 | Bicyclic compounds as Pim inhibitors | AMGEN INC. (US) | 2015-07-28 | — | — | US | disclosed |
| EP-2796456-A1 | Bicyclic compounds as Pim inhibitors | Amgen Inc. (US) | 2014-10-29 | — | — | EP | disclosed |
| US-20140187553-A1 | Azole Compounds as PIM Inhibitors | AMGEM INC. (US) | 2014-07-03 | — | — | US | disclosed |
| US-20140031360-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2014-01-30 | — | — | US | disclosed |
| EP-2688886-A1 | AZOLE COMPOUNDS AS PIM INHIBITORS | Amgen Inc. (US) | 2014-01-29 | — | — | EP | disclosed |
| EP-2649065-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | Amgen Inc. (US) | 2013-10-16 | — | — | EP | disclosed |
| WO-2012129338-A1 | AZOLE COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2012-09-27 | — | — | WO | disclosed |
| WO-2012078777-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140187553-A1 | Azole Compounds as PIM Inhibitors | PIM1, PIM3, PIM2 | KMT2A 761/4885MEN1 2928/4885TSHR 4495/4885 |
| US-20140031360-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | PIM1, PIM2, PIM3 | KMT2A 663/4885MEN1 4135/4885TSHR 4529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.